Webinars
Available On Demand
What do ‘pricing inflation penalties’ actually mean for manufacturers of biopharma products?
Explore the impact of the Inflation Reduction Act (IRA) on biopharmaceutical product net prices and contract strategies as manufacturers adapt to new U.S. market conditions.
In this webinar, Trinity Life Sciences’ Evidence, Value, Access & Pricing practice experts will provide a high-level review of IRA policy updates before exploring the implications for currently marketed Medicare Part B and Part D therapies, as well as for future product launches.…
Watch Now
Webinars
Available On Demand
The U.S. market access landscape is becoming increasingly competitive and complex. It is now more important than ever for drug manufacturers to keep abreast of what payers are thinking to maximize the likelihood of receiving favorable reimbursement outcomes.
Through in-depth and ongoing conversations with Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs), Trinity’s Value, Access and Pricing experts uncover what payers believe to be the most critical factors shaping pricing and market access decision-making for manufacturers over the next…
Watch Now
Blog
Published August 12, 2022
Long-awaited Medicare price negotiations look more like statutory discounts than the value-based negotiations seen in global healthcare systems; combined with expanded price increase rebates and out of pocket limits, new regulation may drive prices for new drugs up more than down. Trinity explores the impact and implications for manufacturers of innovative medicines.
Headline Summary:
After over a year of drafting, Congress recently passed the Inflation Reduction Act, and on August 16th President Biden formally signed the act into law
The…
Read Now
Blog
Published July 20, 2022
Summary
Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers
In contrast, biosimilar versions of adalimumab have been available in most countries outside the U.S. since 2018, resulting in high pricing disparities between immunology and inflammatory treatments between the U.S. and other markets
Trinity’s Take
Adalimumab biosimilar competition in Europe, as well as policy and payer pressure, has exerted downward pricing pressure for…
Read Now
Case Studies
Trinity provided early P&MA forecasting support for a pipeline asset in development for several inflammatory conditions via secondary research.
Geographic Scope:
Client Situation
The client wanted to uncover the optimal launch strategy for their pipeline asset by understanding the current and future landscape across several inflammatory diseases to support indication prioritization.
Trinity’s Solution
Trinity conducted secondary research into the clinical treatment algorithms and current pricing and market access (P&MA) landscape of 19 inflammatory diseases to understand the unmet need, level of competition, payer management, contracting…
Read Now
Blog
Published August 2, 2021
Executive Summary:
A CMS regulation from the Trump Administration requiring hospitals to post lists containing the list price, negotiated private payer prices, and self-pay rates for up to 300 shoppable services took effect in January 2021 but is still widely ignored by hospitals
A lack of enforcement coupled with minor penalties decreases the efficacy of the requirement, resulting in low incentive for hospitals to comply with the rule
The data posted by compliant hospitals shows large variation in pricing for…
Read Now
Webinars
Available On Demand
Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle.
But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?
What are the ‘nuts and bolts’ of designing and conducting such studies?
How do you distill down to the key value messages from a complex data set to be most impactful to clinical…
Watch Now
Case Studies
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.
Geographic Scope:
Client Situation
The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.
Trinity’s Solution
Trinity conducted comprehensive secondary research in the following areas:
Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…
Read Now
Case Studies
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
Geographic Scope:
Client Situation:
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity’s Solution
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses,…
Read Now
Case Studies
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets.
Geographic Scope:
Client Situation
The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy.
Trinity’s Solution
Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space.
Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…
Read Now
